Can patients safely stop Anti-Rejection meds sooner after transplant?
NCT ID NCT07302776
First seen Jan 04, 2026 · Last updated Jun 13, 2026 · Updated 23 times
Summary
This study tests whether it is safe and feasible for certain patients to stop taking tacrolimus, an anti-rejection drug, early after a stem cell transplant. The goal is to reduce side effects while still preventing graft-versus-host disease (GVHD). About 50 adults with blood cancers like AML or MDS will be enrolled. The approach uses modern GVHD prevention methods to allow earlier drug cessation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
Palo Alto, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.